Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
You Li *Department of Pediatrics, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0001-5458-6009
Xin Zheng *Department of Virology II, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.ORCID 0000-0002-4944-6762
Ling XieDepartment of Biochemistry and Biophysics, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Maryna KapustinaDepartment of Cell Biology and Physiology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Takayoshi ShirasakiDepartment of Microbiology and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Bryan YonishLineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Xian ChenDepartment of Biochemistry and Biophysics, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Asuka Hirai-YukiResearch Center for Biosafety, Laboratory Animal and Pathogen Bank, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.ORCID 0000-0002-1218-8333
Noriyo NagataDepartment of Pathology, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.ORCID 0000-0001-9147-1438
Ryosuke SuzukiDepartment of Virology II, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.ORCID 0000-0003-0296-8843
Masanori IsogawaDepartment of Virology II, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.ORCID 0000-0001-8730-4303
Matthew R VogtDepartment of Pediatrics, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0002-4204-5827
Masamichi MuramatsuDepartment of Virology II, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.ORCID 0000-0002-0153-3533
Stanley M LemonDepartment of Microbiology and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0003-1450-806X
Funding
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
Membrane Hijacking: Biogenesis and Fate of Quasi-Enveloped HepatovirusR01AI103083 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LEMON, STANLEY M. · 2012 to 2021
$4.0M
Critical Lipid Species in the Hepatovirus LifecycleR01AI150095 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LEMON, STANLEY M. · 2020 to 2024
$2.6M
Human antibody modification of enterovirus D68 infectionK08AI156125 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI VOGT, MATTHEW R · 2021 to 2025
$900k
Molecular mechanisms of CIB1 signalingR01GM133107 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CHEN, XIAN · 2019 to 2020
$617k
Novel brain-penetrant drugs for translation-targeting therapeutics of Alzheimer’s diseaseR41AG085859 · NIA · TRANSCHROMIX, LLC. · PI CHEN, XIAN · 2024 to 2024
$497k
Deciphering the non-canonical function of the histone methyltransferase G9a in the etiology of ADR21AG071229 · NIA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CHEN, XIAN · 2021 to 2022
$428k
Novel therapeutic intervention of early-stage T1DR41DK133051 · NIDDK · TRANSCHROMIX, LLC. · PI CHEN, XIAN · 2023 to 2023
HSP90 heat shock chaperones are essential for maintaining cellular proteostasis, as well as the ATP-dependent folding and functional maturation of many viral proteins. As a result, inhibitors of HSP90 have broad antiviral activity, disrupting replication of many viruses at concentrations below those causing cytotoxicity. Among the
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Heat shock protein 90 chaperone activity is required for hepatitis A virus replication. · full record | OpenQuestion